Unlike gene-edited CAR T-cell therapies, this approach does not cut the genome to knock out, or knock in, a gene, says Celyad.
Read more: https://www.biopharma-reporter.com/Article/2018/08/15/US-FDA-approves-first-non-gene-edited-allogeneic-CAR-T-cell-candidate-for-trials?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright